Literature DB >> 29621614

Ras and Rap1: A tale of two GTPases.

Seema Shah1, Ethan J Brock1, Kyungmin Ji2, Raymond R Mattingly3.   

Abstract

Ras oncoproteins play pivotal roles in both the development and maintenance of many tumor types. Unfortunately, these proteins are difficult to directly target using traditional pharmacological strategies, in part due to their lack of obvious binding pockets or allosteric sites. This obstacle has driven a considerable amount of research into pursuing alternative ways to effectively inhibit Ras, examples of which include inducing mislocalization to prevent Ras maturation and inactivating downstream proteins in Ras-driven signaling pathways. Ras proteins are archetypes of a superfamily of small GTPases that play specific roles in the regulation of many cellular processes, including vesicle trafficking, nuclear transport, cytoskeletal rearrangement, and cell cycle progression. Several other superfamily members have also been linked to the control of normal and cancer cell growth and survival. For example, Rap1 has high sequence similarity to Ras, has overlapping binding partners, and has been demonstrated to both oppose and mimic Ras-driven cancer phenotypes. Rap1 plays an important role in cell adhesion and integrin function in a variety of cell types. Mechanistically, Ras and Rap1 cooperate to initiate and sustain ERK signaling, which is activated in many malignancies and is the target of successful therapeutics. Here we review the role activated Rap1 in ERK signaling and other downstream pathways to promote invasion and cell migration and metastasis in various cancer types.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell-adhesion; EMT; ERK/MAPK; FTI; Integrins; Metabolism; Rap1; Rap1Gap; Ras

Mesh:

Substances:

Year:  2018        PMID: 29621614      PMCID: PMC6170734          DOI: 10.1016/j.semcancer.2018.03.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  227 in total

1.  Prenylation of mammalian Ras protein in Xenopus oocytes.

Authors:  R Kim; J Rine; S H Kim
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

Review 2.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

Review 3.  Pancreatic adenocarcinoma.

Authors:  David P Ryan; Theodore S Hong; Nabeel Bardeesy
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

4.  Phosphorylation of Rap1 by cAMP-dependent Protein Kinase (PKA) Creates a Binding Site for KSR to Sustain ERK Activation by cAMP.

Authors:  Maho Takahashi; Yanping Li; Tara J Dillon; Philip J S Stork
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

5.  Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.

Authors:  T Tanaka; T H Rabbitts
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

6.  Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway.

Authors:  Shigetomo Fukuhara; Atsuko Sakurai; Hideto Sano; Akiko Yamagishi; Satoshi Somekawa; Nobuyuki Takakura; Yoshihiko Saito; Kenji Kangawa; Naoki Mochizuki
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

7.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

8.  A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Authors:  Carolyn Bentley; Stefanie S Jurinka; Noelyn M Kljavin; Steffan Vartanian; Sree R Ramani; Lino C Gonzalez; Kebing Yu; Zora Modrusan; Pan Du; Richard Bourgon; Richard M Neve; David Stokoe
Journal:  Biochem J       Date:  2013-06-01       Impact factor: 3.857

Review 9.  Exploiting the bad eating habits of Ras-driven cancers.

Authors:  Eileen White
Journal:  Genes Dev       Date:  2013-10-01       Impact factor: 11.361

10.  Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

Authors:  Seung-Min Shin; Dong-Ki Choi; Keunok Jung; Jeomil Bae; Ji-Sun Kim; Seong-Wook Park; Ki-Hoon Song; Yong-Sung Kim
Journal:  Nat Commun       Date:  2017-05-10       Impact factor: 14.919

View more
  51 in total

1.  Transcriptome analysis to identify the Ras and Rap1 signal pathway genes involved in the response of TM3 Leydig cells exposed to zearalenone.

Authors:  Mingyang Wang; Nan Wang; Jingjing Tong; Jiawen Pan; Miao Long; Peng Li
Journal:  Environ Sci Pollut Res Int       Date:  2018-09-06       Impact factor: 4.223

2.  A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

Authors:  Razelle Kurzrock; Douglas W Ball; Steven I Sherman; Nilofer S Azad; Marianna L Zahurak; Barry D Nelkin; Vivek Subbiah; Shabina Ahmed; Ashley O'Connor; Enusha Karunsena; Rose M Parkinson; Justin A Bishop; Yoonji Ha; Rajni Sharma; Christopher D Gocke; Ralph Zinner; Michelle A Rudek
Journal:  Clin Cancer Res       Date:  2019-06-11       Impact factor: 12.531

3.  Identification of two potential immune-related biomarkers of Graves' disease based on integrated bioinformatics analyses.

Authors:  Yihan Zhang; Jia Wei; Hong Zhou; Bingxin Li; Ying Chen; Feng Qian; Jingting Liu; Xin Xie; Huanbai Xu
Journal:  Endocrine       Date:  2022-08-13       Impact factor: 3.925

4.  Constructing a novel prognostic signature of tumor driver genes for breast cancer.

Authors:  Liqiang Zhou; Yali Yi; Chuan Liu; Zhiqing Chen
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

5.  Network Pharmacology-Based Exploration of the Therapeutic Mechanisms of Cordyceps cicadae in Renal Ischemia/Reperfusion.

Authors:  Jiajun Dong; Mingyang Cao; Hui Yu; Yang Dong; Conghui Han
Journal:  Ann Transplant       Date:  2022-09-30       Impact factor: 1.479

Review 6.  The Mystery of Rap1 Suppression of Oncogenic Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Anna A Sablina
Journal:  Trends Cancer       Date:  2020-03-02

7.  Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa-miR-6887-3p.

Authors:  Haixia Li; Jinghui Liang; Jiang Wang; Jingyi Han; Shuang Li; Kai Huang; Chuanyong Liu
Journal:  Cancer Commun (Lond)       Date:  2021-02-27

8.  Identification and preliminary validation of a four-gene signature to predict metastasis and survival in osteosarcoma.

Authors:  Yiming Zhang; Xuan Lei; Rong He; Lianghao Mao; Pan Jiang; Chenlie Ni; Xinyu Zhong; Zhengyu Yin; Xuan Wu; Dapeng Li; Qiping Zheng
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

9.  Parallel Rap1>RalGEF>Ral and Ras signals sculpt the C. elegans nervous system.

Authors:  Jacob I Mardick; Neal R Rasmussen; Bruce Wightman; David J Reiner
Journal:  Dev Biol       Date:  2021-05-13       Impact factor: 3.148

10.  Molecular Interplays Between Cell Invasion and Radioresistance That Lead to Poor Prognosis in Head-Neck Cancer.

Authors:  Guo-Rung You; Joseph T Chang; Yan-Liang Li; Yin-Ju Chen; Yu-Chen Huang; Kang-Hsing Fan; Yen-Chao Chen; Chung-Jan Kang; Ann-Joy Cheng
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.